ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

3:00PM-4:30PM: Abstract Number: 0854

The OMERACT GCA Phantom Project: Validation of 3D Printed Ultrasound Training Models for Giant Cell Arteritis

Abstracts: Imaging of Rheumatic Diseases

3:00PM-4:30PM: Abstract Number: 0840

The Platelet Adenosinergic Axis as a Novel Therapeutic Target for Thrombotic APS

Abstracts: Antiphospholipid Syndrome

3:00PM-4:30PM: Abstract Number: 0846

Three Novel Metabolomic Signatures of Inflammation for Female Gout Risk: A Prospective Cohort Study over 26 Years

Abstracts: Epidemiology & Public Health I

3:00PM-4:30PM: Abstract Number: 0862

Two-year’s Worsening of Semi-quantitative MRI Features as Surrogate Outcomes for Long-term Incident Radiographic Knee Osteoarthritis After ACL-rupture

Abstracts: Osteoarthritis – Novel Insights from Observational Studies

3:00PM-4:00PM: Abstract Number: PP16

Utilization of My Knee Notes for Enhanced Healthcare Management

Patient Perspectives

3:00PM-4:30PM: Abstract Number: 0845

Weight Loss, Disease Activity, and Patient Reported Outcomes in Patients with Musculoskeletal and Autoimmune Diseases Taking Weight Loss Therapies

Abstracts: Epidemiology & Public Health I

3:00PM-4:30PM: Abstract Number: 0865

Z’s and Knees: Associations of Participant-reported and Objective Sleep Measures with Pain Among US Veterans with Osteoarthritis of the Knee

Abstracts: Osteoarthritis – Novel Insights from Observational Studies

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].